Natalie Köhler
Principal Investigator
Department of Hematology, Oncology and Stem-Cell Transplantation
Medical Center University of Freiburg
Breisacher Str. 115
79106 Freiburg
Current position
Academic training
| 2006 - 2011 | Diploma in Molecular Medicine, University of Freiburg |
| 01/11 - 12/11 | Diploma thesis, Johns Hopkins School of Medicine, Baltimore, USA |
Advanced academic qualifications
| 2015 | PhD in Molecular Medicine (summa cum laude), Spemann Graduate School of Biology and Medicine, University of Freiburg |
Postgraduate positions
| Since 05/2021 | Juniorprofessorship (tenure track) for precision targeting of signalling, Department of Haematology, Oncology and Stem Cell Transplantation, Medical Center University of Freiburg |
| 05/19 - 05/21 | Junior group leader, Medical Center University of Freiburg |
| 09/19 - 11/19 | Research Fellowship, Stanford University, USA |
| 2018 - 2019 | Postdoctoral Researcher, Medical Center University of Freiburg |
| 2015 - 2017 | Medical Trainee and Medical Manager Haematology & Oncology, Roche Pharma AG |
| 2012 - 2015 | PhD in Molecular Medicine, Spemann Graduate School of Biology and Medicine, University of Freiburg |
Miscellaneous (Honors, Awards)
| 2020/21 | Selected for participation in the 70th Lindau Nobel Laureate Meeting |
| 2020 | EQUIP Medical Scientist Scholarship, Faculty of Medicine, University of Freiburg |
| 2019 | Grünewald-Zuberbier-Stiftung scholarship for research rotation at Stanford University |
| 2019 | Mechtild Harf Research Grant, DKMS |
| 2018 | EIRA Mentoring Program, Faculty of Medicine, University of Freiburg |
| 2015 | ASH Abstract Achievement Award, ASH Annual Meeting, USA |
| 2015 | DAG-KBT Research Award (German Working Group for Blood and Marrow Transplantation) |
| 2014 | Barbara Hobom Prize for excellent female scientists, BIOSS, Freiburg |
| 2014 | ASH Abstract Achievement Award, ASH Annual Meeting, USA |
| 2014 | Travel grant for research visit at the University of Adelaide (AC21 program) |
| 2012 | SGBM 3-year PhD scholarship (Excellence Initiative) |
| 2011 | Carl Duisberg scholarship (Bayer fellowship program) for diploma thesis in the USA |
| 2006 | Karl-von-Frisch Preis Baden-Württemberg for outstanding achievements in biology |
Publications listed in PubMed®
Publications (based on CRC1479 funding)
Maas-Bauer K, Köhler N, Stell AV, Zwick M, Acharya S, Rensing-Ehl A, König C, Kroll J, Baker J, Koßmann S, Pradier A, Wang S, Docquier M, Lewis DB, Negrin RS, Simonetta F. Single-cell transcriptomics reveal different maturation stages and sublineage commitment of human thymic invariant natural killer T cells. J Leukoc Biol. 2024 Jan 19;115(2):401-409. doi: 10.1093/jleuko/qiad113.
Nelde A, Schuster H, Heitmann JS, Bauer J, Maringer Y, Zwick M, Volkmer JP, Chen JY, Stanger AMP, Lehmann A, Appiah B, Märklin M, Rücker-Braun E, Salih HR, Roerden M, Schroeder SM, Häring MF, Schlosser A, Schetelig J, Schmitz M, Boerries M, Köhler N, Lengerke C, Majeti R, Weissman IL, Rammensee HG, Walz JS. Immune Surveillance of Acute Myeloid Leukemia Is Mediated by HLA-Presented Antigens on Leukemia Progenitor Cells. Blood Cancer Discov. 2023 Nov 1;4(6):468-489. doi: 10.1158/2643-3230.BCD-23-0020.
Rückert T, Andrieux G, Boerries M, Hanke-Müller K, Woessner NM, Doetsch S, Schell C, Aumann K, Kolter J, Schmitt-Graeff A, Schiff M, Braun LM, Haring E, Kissel S, Siranosian BA, Bhatt AS, Nordkild P, Wehkamp J, Jensen BAH, Minguet S, Duyster J, Zeiser R, Köhler N. Human β-defensin 2 ameliorates acute GVHD by limiting ileal neutrophil infiltration and restraining T cell receptor signaling. Sci Transl Med. 2022 Dec 21;14(676):eabp9675. doi: 10.1126/scitranslmed.abp9675. Epub 2022 Dec 21. PMID: 36542690.
free full text: https://www.science.org/stoken/author-tokens/ST-951/full
Bauer J, Köhler N, Maringer Y, Bucher P, Bilich T, Zwick M, Dicks S, Nelde A, Dubbelaar M, Scheid J, Wacker M, Heitmann JS, Schroeder S, Rieth J, Denk M, Richter M, Klein R, Bonzheim I, Luibrand J, Holzer U, Ebinger M, Brecht IB, Bitzer M, Boerries M, Feucht J, Salih HR, Rammensee HG, Hailfinger S, Walz JS. The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinoma. Nat Commun. 2022 Oct 27;13(1):6401. doi: 10.1038/s41467-022-33746-3.
Ho JNHG, Schmidt D, Lowinus T, Ryoo J, Dopfer EP, Gonzalo Núñez N, Costa-Pereira S, Toffalori C, Punta M, Fetsch V, Wertheimer T, Rittmann MC, Braun LM, Follo M, Briere C, Vinnakota JM, Langenbach M, Koppers F, Shoumariyeh K, Engel H, Rückert T, Märklin M, Holzmayer S, Illert AL, Magon F, Andrieux G, Duquesne S, Pfeifer D, Staniek J, Rizzi M, Miething C, Köhler N, Duyster J, Menssen HD, Boerries M, Buescher JM, Cabezas-Wallscheid N, Blazar BR, Apostolova P, Vago L, Pearce EL, Becher B, Zeiser R. Targeting MDM2 enhances antileukemia immunity after allogeneic transplantation via MHC-II and TRAIL-R1/2 upregulation. Blood. 2022 Sep 8;140(10):1167-1181. doi: 10.1182/blood.2022016082.
Highlighted by this Editorial: Bleakley M, Biernacki M. MDM2 inhibition augments GVL effect. Blood. 2022 Sep 8;140(10):1064-1065. doi: 10.1182/blood.2022017724. PMID: 36074535.
Avery TY, Köhler N, Zeiser R, Brummer T, Ruess DA. Onco-immunomodulatory properties of pharmacological interference with RAS-RAF-MEK-ERK pathway hyperactivation. Front Oncol. 2022 Jul 27;12:931774. doi: 10.3389/fonc.2022.931774.
Haring E, Andrieux G, Uhl FM, Krausz M, Proietti M, Sauer B, Esser PR, Martin SF, Pfeifer D, Schmitt-Graeff A, Duyster J, Köhler N, Grimbacher B, Boerries M, Aumann K, Zeiser R, Apostolova P. Therapeutic targeting of endoplasmic reticulum stress in acute graft-versus-host disease. Haematologica. 2022 Jul 1;107(7):1538-1554. doi: 10.3324/haematol.2021.278387.
Köhler N, Zeiser R. Epigenetic Regulation to Enhance Graft-versus-Leukemia Activity. Cancer Discov. 2022 Jun 2;12(6):1410-1412.
Contact
